New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 27, 2014
11:10 EDTTKPYY, FURXFuriex confirms Takeda to present additional EXAMINE trial data
Furiex Pharmaceuticals (FURX) confirmed that its partner Takeda Pharmaceuticals (TKPYY) will present sub-analyses from the global EXAMINE, EXamination of CArdiovascular OutcoMes: AlogliptIN vs. Standard of CarE in Patients with Type 2 Diabetes Mellitus and Acute Coronary Syndrome, cardiovascular safety outcomes trial in a poster session at the American College of Cardiology’s 63rd Annual Scientific Session. These sub-analyses specifically relate to the effects of alogliptin on rates of CV mortality and hospitalization for heart failure, Furiex said. Findings from one sub-analysis demonstrated no effect on rates of CV mortality. There was also no increase in sudden cardiac death with alogliptin. The other sub-analysis demonstrated that in patients with Type 2 diabetes and recent ACS, the pre-specified composite CV outcome of first occurrence of all-cause mortality, nonfatal myocardial infarction and stroke, urgent revascularization due to unstable angina, and hospitalization for heart failure was similar for alogliptin compared with placebo.
News For FURX;TKPYY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 30, 2015
05:16 EDTTKPYYTeva enters partnership with Takeda Pharmaceutical
Subscribe for More Information
November 20, 2015
16:55 EDTTKPYYTakeda confirms FDA approval of Ninlaro
Takeda Pharmaceutical Company Limited announced that the FDA has approved Ninlaro capsules, the first and only oral proteasome inhibitor, indicated in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received at least one prior therapy.
10:52 EDTTKPYYFDA approves new oral medication to treat multiple myeloma
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use